Brief: LTR Pharma Secures First U.S. Commercial Agreement For Roxus
09/06/2026 24:54
BRIEF-LTR Pharma Secures First U.S. Commercial Agreement For Roxus June 9 (Reuters) - LTR Pharma Ltd LTP.AX:
LTR SECURES FIRST U.S. COMMERCIAL AGREEMENT FOR ROXUS
MINIMUM COMMERCIAL VOLUME TARGET OF 150,000 ROXUS UNITS IN FIRST 12 MONTHS FROM LAUNCH
Further company coverage: LTP.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ltr Pharma
See all newsAustralia's LTR Pharma surges as its drug begins US prescription fulfillment
Brief: LTR Pharma Executes Exclusive Pilot Agreement With Marius Pharmaceuticals, Inc For Kyzatrex
Brief: LTR Pharma Executes U.S. Commercial Agreement With Strive
Australia's LTR Pharma rises on commercial tie-up with US telehealth firm
Australia's LT Pharma gains after nod to test nasal spray